Novo Medi Sciences, a pharmaceutical company with 80 years of expertise in niche biological products, has launched Nexipox Plus, marking the most significant innovation in the varicella vaccine in decades. 

 

The vaccine has been specifically developed to meet the clinical, environmental, and operational needs of Indian patients, making Novo Medi Sciences the only company proactively upgrading varicella vaccination for India.

 

Live attenuated varicella vaccines are notoriously thermolabile, making formulation stability and potency critical. Nexipox Plus addresses these challenges with a 2X trehalose-based stabiliser system, replacing conventional stabilisers such as gelatin and mannitol. 

 

This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues—ensuring reliable vaccine performance across storage, handling, and administration.

 

Clinical trials demonstrate strong immunogenicity. Forum Bhagat, Managing Director of Novo Medi Sciences, said, "Nexipox Plus reflects our commitment to advancing vaccine science beyond incremental changes. The results of the clinical trial on Indian Patients has shown high seroconversion rates of 98% following a two-dose schedule, supported by a 35.4-fold geometric mean rise in antibody titres, indicating a robust immune response and effective protection against varicella virus.”

 

The vaccine has also shown a favourable safety profile, with no serious adverse events causally linked to it in comparative trials. Removal of gelatin further enhances tolerability.

 

Dr Nitin K Shah, Consultant Pediatrician and Pediatric Hemato-Oncologist, highlighted its clinical relevance: “While stability and safety are already well established in varicella vaccination, the real clinical advancement with Nexipox Plus lies in its enhanced immunogenicity. By building on a stable and reliable formulation, the use of 2× trehalose alongside advances in formulation and manufacturing has translated into stronger and more consistent immune responses, offering tangible benefits in routine immunisation and reinforcing clinician confidence.”

 

With chickenpox prevalence still high in India, Nexipox Plus aligns with public health goals to reduce disease burden and improve vaccination compliance. Designed for affordability, scalability, and operational reliability, it supports private practice adoption and strengthens the overall immunisation ecosystem.

 

Approved by the Drugs Controller General of India (DCGI) for use from 12 months of age, the vaccine leverages patented technology across 156 countries, with international expansion strategies under evaluation.

 

With Nexipox Plus, Novo Medi Sciences reaffirms its commitment to formulation-led vaccine innovation, delivering advancements in stability, safety, and clinical confidence for modern immunisation practices.